A major independent review, this analysis has cast serious doubt on the real-world value of new “breakthrough” Alzheimer’s drugs. These treatments – such as donanemab and lecanemab – target beta amyloid, a protein that accumulates in the brains of people with Alzheimer’s disease. While clinical trials showed they can modestly slow cognitive decline, the review of 17 studies involving over 20,000 participants concluded that the benefits are too small to meaningfully improve patients’ lives.
The analysis also highlighted practical and medical drawbacks. These drugs must be administered frequently – every two to four weeks – and come with significant risks, including brain swelling and bleeding. With private treatment costs reaching around £90,000 ($122,000) for an 18-month course, access is already highly limited. Experts argue that patients should be given realistic expectations, suggesting most are unlikely to experience noticeable benefit and warning against raising false hope.
To read how a recent scientific review has shown that Alzheimer’s disease is closely linked to deficiencies in essential vitamins, see this article on our website.
Early Folic Acid Supplementation May Halve the Risk of Birth Defects in Women Using Antiseizure Medication
April 24, 2026Deep-Fried Food to be Banned Under New School Dinner Plans in England
April 24, 2026Breakthrough Alzheimer’s Drugs Unlikely to Benefit Patients, Report Suggests
News
Influential analysis has concluded that “breakthrough” Alzheimer’s drugs are unlikely to benefit patients. Researchers said the impact was “well below” what was needed to make a difference to dementia patients’ lives.
[Source: bbc.co.uk]
[Image source: freepik.com]
Comment
A major independent review, this analysis has cast serious doubt on the real-world value of new “breakthrough” Alzheimer’s drugs. These treatments – such as donanemab and lecanemab – target beta amyloid, a protein that accumulates in the brains of people with Alzheimer’s disease. While clinical trials showed they can modestly slow cognitive decline, the review of 17 studies involving over 20,000 participants concluded that the benefits are too small to meaningfully improve patients’ lives.
The analysis also highlighted practical and medical drawbacks. These drugs must be administered frequently – every two to four weeks – and come with significant risks, including brain swelling and bleeding. With private treatment costs reaching around £90,000 ($122,000) for an 18-month course, access is already highly limited. Experts argue that patients should be given realistic expectations, suggesting most are unlikely to experience noticeable benefit and warning against raising false hope.
To read how a recent scientific review has shown that Alzheimer’s disease is closely linked to deficiencies in essential vitamins, see this article on our website.
Dr. Rath Health Foundation
Related posts
Slovakia to Challenge EU Deregulation of Gene Editing in Court
Read more